There is emerging evidence supporting the addition of Polatuzumab vedotin for high-risk DLCBL, the addition of Bortezomib in ABC-DLBCL, or the use of dose-adjusted EPOCH plus Rituximab for patients expressing high levels of MYC and BCL2 [39–41]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.